TP53 and lymphoma: Cell viability assays revealed that concentrations of APR-246 that can be achieved in human patients in ongoing clinical trials (personal communication Lars Abrahmsen, Aprea) were able to kill Eμ-Myc lymphoma cell lines that were TRP53 WT, TRP53 mutant and TRP53 deficient.